Faster radiotherapy more effective in head and neck cancer, trial shows

September 18, 2003

The world's largest trial in accelerated radiotherapy for head and neck cancer - the DAHANCA trial - proves conclusively that increasing the number of treatments per week from five to six can benefit patients.

The research is published tomorrow (Saturday 20 September) in The Lancet medical journal[1] and the results will also be presented next week at ECCO 12 - the European Cancer Conference[2], taking place in Copenhagen, Denmark.

Principal investigator Professor Jens Overgaard, from Aarhus University Hospital, Aarhus, Denmark, said that results from DAHANCA meant that the standard radiotherapy treatment for head and neck cancer had now changed.

In the trial, 1476 head and neck cancer patients were randomised to receive the same amount of radiotherapy per week, the only difference between the groups being the frequency with which they received it. One group had five treatments per week, and the other six. Overall, the results showed a benefit in tumour control of 60% in the 5 x week group, and 70% in the group receiving six treatments. The 6 x week group also showed better voice conservation in the patients with laryngeal cancer (80% as opposed to 68%). The patients were at different stages of the disease, from early to very advanced, but all were indicated for primary radiotherapy.

"Although all patients in the accelerated treatment arm did better," said Professor Overgaard, "some did better than others, and we are currently trying to identify those groups where the benefit is largest. It appears to be linked to two factors - a high degree of expression of epidermal growth factor receptor (EGFR) and a good differentiation of the tumour."

An unpublished meta-analysis of trials[3] of modified fractionated radiotherapy in head and neck cancer, with about 8000 patients in all, also supports these findings, he said. "There are no shades of grey", said Professor Overgaard. These findings are unequivocal - accelerated treatment is definitely better in this cancer, both in terms of disease-specific survival and in quality of life."

Members of DAHANCA - the Danish head and neck cancer group - have been working together for 25 years. "What we have shown is that, with national collaboration and multidisciplinary, co-operative working, it is possible to run large-scale, but inexpensive, trials in small countries which can improve practice throughout the world," said Professor Overgaard.
[1] Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. The Lancet. Vol 362. September 20, 2003 pp 933-940.

[2] ECCO 12 abstract no: 1.065 (Thursday 25 September 09.30 hrs CET, FECS/EJC award presentations session)

[3] Abstract no: 678 (Wednesday 24 September 10.45 hrs CET, Head and neck cancer session)

ECCO-the European CanCer Organisation

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to